Research programme: DNA oligonucleotides - ProMetic Life Sciences

Drug Profile

Research programme: DNA oligonucleotides - ProMetic Life Sciences

Alternative Names: BT 99-25; DNA oligonucleotides research programme - Telesta

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Bioniche Life Sciences
  • Developer ProMetic Life Sciences
  • Class Oligonucleotides
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Leukaemia

Most Recent Events

  • 31 Oct 2016 Telesta Therapeutics has been acquired and merged into ProMetic Life Sciences
  • 24 Aug 2016 ProMetic Life Sciences plans to acquire Telesta Therapeutics in November 2016
  • 13 Nov 2014 Bioniche Life Sciences is now called Telesta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top